跳至主要内容
临床试验/CTRI/2024/04/065579
CTRI/2024/04/065579尚未招募2 期

A clinical study on Aurokid Plus tablet as adjuvant therapy in the management of pediatric Myoclonic Epilepsy - A proof of concept

Parul University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年4月22日最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
20
试验地点
1
主要终点
Improvement on Cognition on the basis of Binnet Kamat Scale and MMAS

研究概览

简要总结

Myoclonic epilepsy is neurobehavioral disorder affectinf tje cognition of child with social stigma. Ayurveda having multiple herbomineral drug to improve the cognitionand to improve the quality of life of children with epilepsy, Aurokid Plus is special gold salt Ayurveda Proprietory medicine used in childhood neurobahvioral diseases. Present study is aiming towards to evaluate the effect of tablet as an adjuvant therapy in childhood myoclonic epilepsies

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
5.00 Year(s) 至 12.00 Year(s)(—)
性别
All

入选标准

  • Childhood ME and its type Prediagnosed cases minimum chronicity 6 months and less than 5 years.

排除标准

  • Acute and Chronic systemic diseases episodes of 2 or more status epilepticus in last 6 months.

结局指标

主要结局

Improvement on Cognition on the basis of Binnet Kamat Scale and MMAS

时间窗: day 30 and day 60

次要结局

  • Improvement in Quality of life on basis WHO QoL Questioner 55(day 30 & day 60)

研究者

申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Dr. Priyal Patel

Parul Institute of Ayurved

研究点 (1)

Loading locations...

相似试验